Biogen (BIIB.US) stock has been halted after the FDA has approved its controversial Alzheimer drug Aducanumab using an accelerated approval pathway. It is the first Alzheimer's treatment approved in 18 years, according to CNBC. Biogen still needs to conduct a postapproval clinical trial and FDA pointed out that the approval may be withdrawn upon unfavorable results.
Biogen (BIIB.US) stock was halted for trading at $286.10 and awaits reopening. Source: xStation5
Boeing gains amid news about potential huge 737 MAX order from China 📈
Wall Street tries to stop the deeper decline 🗽Marvell Technology jumps 10%
RyanAir shares under pressure amid Middle East conflict 📉
Stock of the Week: Broadcom Driven by AI Sets Records